Publisher
Springer Science and Business Media LLC
Reference42 articles.
1. European Medicines Agency. Shortage of Visudyne (verteporfin). 5 November 2021. https://www.ema.europa.eu/en/documents/shortage/shortage-visudyne-verteporfin-supply-shortage_en.pdf. Accessed 19 July 2023.
2. Tsika C, Mohamed MD, Lotery AJ. Impact of the ongoing worldwide shortage of verteporfin (Visudyne®) on the visual function of patients with chronic central serous chorioretinopathy. Acta Ophthalmol. 2023. https://doi.org/10.1111/aos.15714. Epub ahead of print.
3. Oribio-Quinto C, Fernández-Vigo JI, Bilbao-Malavé V, et al. Anatomical and functional impact of verteporfin shortage in patients with chronic central serous chorioretinopathy. Photodiagn Photodyn Ther. 2023;42: 103501.
4. Gawęcki M, Grzybowski A, Pompein-Batkiewicz M. Significant visual impairment after short-lasting central serous chorioretinopathy. Case Rep Ophthalmol. 2022;13:678–85.
5. Kwiatkowski S, Knap B, Przystupski D, et al. Photodynamic therapy—mechanisms, photosensitizers and combinations. Biomed Pharmacother. 2018;106:1098–107.